Dr. Lori Griner is pictured with her committee following the sucessful defense of her dissertation on December 12, 2012. From left to right: committee member Lynn Moscinski, external chair Peter Sayeski from the University of Florida, Lori Griner, Major Professor Gary Reuther and committee members Alvaro Monteiro and Lori Hazlehurst. Dr. Griner has accepted a postdoctoral fellow position in the lab of Dr. Melvin L. DePamphilis, Section Chief and member of the Senior Biomedical Research Service, National Institute of Child Health and Human Development.
Dr. Griner's publications while in the Program:
Mazzacurati L, Lambert QT, Pradhan A, Griner LN, Huszar D, Reuther GW.
The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells. Oncotarget. 2015 Nov 24;6(37):40141-57. doi: 10.18632/oncotarget.5653.
Griner LN, McGraw KL, Johnson JO, List AF, Reuther GW. JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth. Br J Haematol. 2013 Jan;160(2):177-87. doi: 10.1111/bjh.12103. PMID: 23157224
Griner LN, Reuther GW. Aggressive myeloid leukemia formation is directed by the Musashi 2/Numb pathway. Cancer Biol Ther. 2010 Nov 15;10(10):979-82. PMID: 21084860
Pradhan A, Lambert QT, Griner LN, Reuther GW. Activation of JAK2-V617F by components of heterodimeric cytokine receptors. J Biol Chem. 2010 May 28;285(22):16651-63. doi: 10.1074/jbc.M109.071191. PMID: 20363735